fda compounding semaglutide warning 2025 october is moving to restrict mass-marketed compounded GLP-1 products that aren't FDA-approved, companies they can't market them as equivalent to approved drugs and signaling stronger enforcement to protect patients from unverified Diabetes advocacy group discourages use

While the GLP-1 market is already dominated by established players such as Novo Nordisk and Eli Lilly, JPMorgan believes that the new entrant has the potential to carve out a significant market share

In contrast, the FREEDOM trial reported that the constant infusion of exenatide (20 ug daily for 3 months followed by 60 g daily) through an osmotic minipump was non-inferior to the placebo in 4156 T2DM patients (with a median follow-up of 16 months) (Ruff et al

When to Consider Switching From Semaglutide to Tirzepatide You might benefit from transitioning if youve reached a weight loss plateau, are experiencing challenging side effects, have insurance coverage changes, or your provider recommends optimization based on your progress

[DOI] [PMC free article] [PubMed] [Google Scholar] 36.Zhang M., Yang B., Luan X., Jiang L., Lu C., Wu C., Pan X., Peng T

Twenty-eight patients were assigned to the intervention (continue) group, with 15 undergoing upper endoscopies alone and 13 undergoing both upper endoscopy and colonoscopy (Figure 1)